In-vitro Anti-trypanosomal and Cytotoxicity Evaluation of 3-methyl-3,4-dihydroquinazolin-2(1H)-one Derivatives

Abstract

Sleeping sickness, caused by trypanosomes, is a debilitating, neglected tropical disease wherein current treatments suffer from several drawbacks such as toxicity, low activity, and poor pharmacokinetic properties, and hence the need for alternative treatment is apparent. To this effect, we screened in vitro a library of 2-quinazolinone derivatives for antitrypanosomal activity against T.b. brucei and cytotoxicity against HeLa cells. Seven compounds having no overt cytotoxicity against HeLa cells exhibited antitrypanosomal activity in the range of 0.093–45 µM were identified. The activity data suggests that the antitrypanosomal activity of this compound class is amenable to substituents at N1 and C6 positions. Compound 14 having a molecular weight of 238Da, ClogP value of 1 and a total polar surface area of 49 was identified as the most active, exhibiting an IC₅₀ value of 0.093 µM [Graphical Abstract].

Graphical Abstract.

Key words

sleeping sickness - 2-quinazolinone - hit - antitrypanosomal - cross screening

Publication History

Received: 20 November 2020

Accepted: 05 January 2021

Article published online:
03 February 2021

• References

• 1 Brun R, Schumacher R, Schmid C. et al. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health 2001; 6: 906-914
• 2 Barrett M, Burchmore R, Stich A. et al. The trypanosomiases. Lancet 2003; 362: 1469-1480
• 3 Beteck R, Legoabe L, Isaacs M. et al. In vitro anti-trypanosomal activities of indanone-based chalcones. Drug Research 2019; 69: 337-341
• 4 http://www.who.int/gho/neglected_diseases/human_african_trypanosomiasis/en/ Accessed on 06.11.2020
• 5 Kuepfer I, Hhary E, Allan M. et al. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis 2011; 5: e968
• 6 Simarro P, Cecchi G, Franco J. et al. Estimating and mapping the population at risk of sleeping sickness. PLOS Neglected Tropical Diseases 2012; 6: e1859
• 7 Franco J, Simarro P, Diarra A. et al. Epidemiology of human African trypanosomiasis. Clin Epidemiol 2014; 6: 257-275
• 8 Kaiser M, Bray M, Cal M. et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrobial Agents and Chemotherapy 2011; 55: 5602-5608
• 9 MacLean L, Reiber H, Kennedy P. et al. Stage progression and neurological symptoms in Trypanosoma brucei rhodesience sleeping sickness: Role of the CNS inflammatory response. PLOS Negl Trop Dis 2012; 6: e1857
• 10 Kennedy PG. Human African trypanosomiasis of the CNS: Current issues and challenges. J Clin Invest 2004; 113: 496-504
• 11 Stich A, Abel P, Krishna S. Human African trypanosomiasis. BMJ 2002; 325: 203-206
• 12 Checchi F, Filipe J, Haydon D. et al. Estimates of the duration of the early and late stage of gambiense sleeping sickness. Infect Dis 2008; 8: 1-10
• 13 https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness) Accessed on 06:11:2020
• 14 Berninger M, Schmidt I, Ponte-Sucre A. et al. Novel lead compounds in pre-clinical development against African Sleeping Sickness. Med Chem Commun 2017; 8: 1872-1890
• 15 Babokhov P, Sanyaolu AO, Oyibo WA. et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health 2013; 107: 242-252
• 16 Mesu V, Kalonji B, Bardonneau W. et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: A pivotal multicentre, randomised, non-inferiority trial. The Lancet 2018; 391: 144-154
• 17 Deeks ED. Fexinidazole: first global approval. Drugs 2019; 79: 215-220
• 18 Lindner A, Lejon V, Chappuis F. et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice. The Lancet Infectious Diseases 2020; 20: e38-e46
• 19 Chappuis F. Oral fexinidazole for human African trypanosomiasis. The Lancet 2018; 391: 100-102
• 20 Steverding D. The development of drugs for treatment of sleeping sickness: A historical review. Parasit Vectors 2010; 3: 1-9
• 21 Marais L, Petzer A, Petzer JP. et al. The monoamine oxidase inhibition properties of C6‑ and N1‑substituted 3‑methyl‑3,4‑dihydroquinazolin‑2(1H)‑one derivatives. Molecular Diversity 2019; 24: 391-406
• 22 Burri C. Chemotherapy against human African trypanosomiasis; Is there a road to success?. Parasitol 2010; 137: 1987-1994
• 23 Babokhov P, Sanyaolu A, Oyibo A. et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathogens and Global Health 2013; 107: 242-252
• 24 Ahmed M, Youns M. Synthesis and Biological evaluation of a novel series of 6, 8-D ibromo-4 (3 H) quinazolinone derivatives as anticancer agents. Archiv der Pharmazie 2013; 346: 610-617
• 25 Field M, Horn D, Fairlamb A. et al. Antitrypanosomatid drug discovery: An ongoing challenge and a continuing need. Nat Rev Microbiol 2017; 15: 217-231
• 26 Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. International Journal of Medicinal Chemistry 2014;
• 27 Noureldin N, Kothayer H, Lashine E. et al. Synthesis, anticonvulsant activity, and SAR study of novel 4-quinazolinone derivatives. Archiv der Pharmazie 2017; 350: 1600332
• 28 Mohamed M, Kamel M, Kassem E. et al. Synthesis, biological evaluation and molecular docking of quinazoline-4 (1H)-one derivatives as anti-inflammatory and analgesic agents. Acta Pol Pharm. Drug Res 2011; 68: 665-675
• 29 Zayed M, Hassan M. Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents. Saudi Pharmaceutical Journal 2014; 22: 157-162
• 30 Gatadi S, Lakshmi T, Nanduri S. 4 (3H)-Quinazolinone derivatives: Promising antibacterial drug leads. European Journal of Medicinal Chemistry 2019; 170: 157-172
• 31 Eissa A, El-Metwally A, El-Hashash M. et al. Synthesis and Biological Evaluation of Some New2-propyl-4 (3H)-Quinazolinone Derivatives as Anti-bacteria. Journal of the Korean Chemical Society 2008; 52: 328-337
• 32 Zhang J, Liu J, Ma Y. et al. One-pot synthesis and antifungal activity against plant pathogens of quinazolinone derivatives containing an amide moiety. Bioorganic Medicinal Chemistry Letters 2016; 26: 2273-2277
• 33 Ahmed M, Youns M. Synthesis and Biological Evaluation of a novel series of 6, 8-D ibromo-4 (3 H) quinazolinone derivatives as anticancer agents. Archiv der Pharmazie 2013; 346: 610-617
• 34 Birhan Y, Bekhit A, Hymete A. In vivo antimalarial evaluation of some 2, 3-disubstituted-4 (3 H)-quinazolinone derivatives. BMC Research Notes 2015; 8: 1-6
• 35 Wong WA. Weak spot in multiple protozoan parasites. J Structure 2017; 25: 1641-1643
• 36 Pandey R, Kumbhar B, Srivastava S. et al. Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: Binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation. Journal of Biomolecular Structure 2017; 35: 141-158
• 37 Scovill J, Blank E, Konnick E. et al. Antitrypanosomal activities of tryptanthrins. Antimicrobial Agents and Chemotherapy 2002; 882-883
• 38 Bukachi S, Wandibba S, Nyamongo I. The socio-economic burden of human African trypanosomiasis and the coping strategies of households in the South Western Kenya foci. PLoS Negl Trop Dis 2017; 11: e0006002
• 39 Marais L, Petzer A, Petzer JP. et al. The monoamine oxidase inhibition properties of C6-and N1-substituted 3-methyl-3,4-dihydroquinazolin-2(1H)-one derivatives. Molecular Diversity 2019; 24: 391-406
• 40 Devine W, Woodring JL, Swaminathan U. et al. Protozoan parasite growth inhibitors discovered by cross-screening yield potent scaffolds for lead discovery. J Med Chem 2015; 58: 5522-5537
• 41 Monti L, Wang S, Oukoloff K. et al. Brain-penetrant, triazolopyrimidine and phenylpyrimidine microtubule-stabilizers as potential leads to treat Human African Trypanosomiasis. ChemMedChem 2018; 13: 1751-1754
• 42 Beteck R, Legoabe L, Isaacs M. et al. Anti-Trypanosomal and antimalarial properties of tetralone derivatives and structurally related benzocycloalkanones. Medicina (Kaunas) 2019; 55: 206
• 43 Troeberg L, Chen X, Flaherty T. et al. Chalcone, acyl hydrazide, and related amides kill cultured Trypanosoma brucei brucei. Mol Med 2000; 6: 660-669
• 44 Veale C, Hoppe H. Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery. Med Chem Commun 2018; 9: 2037-2044 . DOI: 10.1039/C8MD00319J
• 45 Field M, Horn D, Fairlamb A. et al. Antitrypanosomatid drug discovery: an ongoing challenge and a continuing need. Nat Rev Microbiol 2017; 15: 217-231
• 46 Beteck R, Isaacs M, Hoppe H. et al. Synthesis, in vitro cytotoxicity and trypanocidal evaluation of novel 1,3,6-substituted non-fluoroquinolones. S Afr J Chem 2018; 71: 188-195
• 47 Bollini M, Bruno A, Niño M. et al. Synthesis, 2D-QSAR studies and biological evaluation of quinazoline derivatives as potent anti-trypanosoma cruzi agents. J Medicinal Chemistry 2019; 15: 265-276